EUVIMEDEUVIMED entdecken
Crossref

Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia

Christian Pfrepper, Carmen Escuriola Ettingshausen, Robert Klamroth, Johannes Oldenburg, Martin Olivieri

Hämostaseologie · 01.06.2026 · 46 (03) · 206-214

DOI: 10.1055/a-2411-7416 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hämostaseologie, erschienen am 01.06.2026. Verfasst von Christian Pfrepper und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany. Hauptthemen laut MEDLINE: Factor VIII, Hemophilia A, Hemorrhage. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prophylaxis is the standard of care for patients with severe hemophilia, patients with moderate hemophilia, or those with another congenital bleeding disorder that is associated with a severe bleeding phenotype and/or a high risk of spontaneous life-threatening bleeding. Patients with nonsevere hemophilia (factor VIII [FVIII] ≥ 1%) may also have a bleeding phenotype that requires prophylaxis. To date, however, there are no clear criteria as to when prophylaxis is indicated in these patients. Also, the term “severe bleeding phenotype (SBPT)” is neither included in the definitions of the International Society on Thrombosis and Haemostasis (ISTH) nor specified in the World Federation of Hemophilia (WFH) guidelines. Based on our personal experience and available evidence, we propose the criteria we use to define an SBPT and when we consider offering prophylaxis in patients with nonsevere hemophilia. Our proposals can be the basis for discussions in the community about the assessment of SBPT and the initiation of prophylaxis in patients with nonsevere hemophilia without inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor VIIIHemophilia AHemorrhageHumansPhenotypePractice Guidelines as Topic

Substanzen

Factor VIII

Autor:innen und Institutionen

  • Division of Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany.
  • Hemophilia Centre Rhein Main (HZRM), Frankfurt, Germany.
  • Vivantes Klinikum im Friedrichshain, Berlin, Germany.
  • Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany.
  • Pediatric Thrombosis and Hemostasis Center, Pediatric Hemophilia Center, Dr. von Hauner Children's Hospital, LMU Munich, Germany.

Zitieren

APA

Pfrepper, C., Ettingshausen, C. E., Klamroth, R., Oldenburg, J., & Olivieri, M. (2026). Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia. Hämostaseologie, 46(03), 206-214. https://doi.org/10.1055/a-2411-7416

Vancouver

Pfrepper C, Ettingshausen CE, Klamroth R, Oldenburg J, Olivieri M. Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia. Hämostaseologie. 2026;46(03):206-214. doi:10.1055/a-2411-7416

BibTeX
@article{Pfrepper2026,
  author = {Pfrepper, Christian and Ettingshausen, Carmen Escuriola and Klamroth, Robert and Oldenburg, Johannes and Olivieri, Martin},
  title = {Expert Opinion for Defining a Severe Bleeding Phenotype to Guide Prophylaxis in Patients with Nonsevere Hemophilia},
  journal = {Hämostaseologie},
  year = {2026},
  volume = {46},
  number = {03},
  pages = {206--214},
  doi = {10.1055/a-2411-7416}
}
Kostenlos starten →